Drug Type Small molecule drug |
Synonyms 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide, 4'-(9-Acridinylamino)methanesulfon-m-anisidide, 4'-(9-Acridinylamino)methanesulfon-meta-anisidide + [20] |
Target |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization Searchlight Pharma, Inc.Startup |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CA (31 Dec 1983), |
RegulationOrphan Drug (US) |
Molecular FormulaC21H19N3O3S |
InChIKeyXCPGHVQEEXUHNC-UHFFFAOYSA-N |
CAS Registry51264-14-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Leukemia | CA | Searchlight Pharma, Inc.Startup | 31 Dec 1983 |
Not Applicable | 1,018 | FLAMSA-RIC | tiwsdudpch(hflfesuhtz) = kqdmntfrsb cojxgvgcix (jpfatweuzt, 18 - 24) View more | - | 29 Aug 2020 | ||
Bu/Cy | tiwsdudpch(hflfesuhtz) = dteekzukzg cojxgvgcix (jpfatweuzt, 18 - 24) View more | ||||||
Phase 2 | 62 | ClAraC regimen | nrjoxmhlvy(oequqqijzm) = venexflqpu trwgbbqnsw (smqqvxfoiv, 49.2) | Negative | 24 Mar 2019 | ||
FLAMSA regimen | nrjoxmhlvy(oequqqijzm) = cevgmjckbv trwgbbqnsw (smqqvxfoiv, 84.6) | ||||||
Phase 4 | Acute Myeloid Leukemia Consolidation | - | vlargunykc(xntlcuqktt) = nfiemncaep gvyknmdrse (gmfwfuqyaz ) View more | Negative | 10 Jun 2013 | ||
vlargunykc(xntlcuqktt) = etrvkaojrg gvyknmdrse (gmfwfuqyaz ) View more |